NEW YORK, May 22, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, today announced the closing of its previously announced underwritten public offering of 4,137,931 shares of its common stock at a public offering price of $14.50 per share. The gross proceeds to Stemline from the public offering are $60 million, before underwriting discounts and commissions and other offering expenses payable by Stemline.
Jefferies LLC and Aegis Capital Corp. acted as joint book-running managers for the offering. Roth Capital Partners acted as co-lead manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on May 16, 2013.
This offering was made by means of a prospectus. Copies of the prospectus relating to this offering may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY, 10022, or by telephone at 877-547-6340, or by email at Prospectus_Department@Jefferies.com or Aegis Capital Corp., Attention: Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY 10019, or by telephone at 212-813-1010, or by email at firstname.lastname@example.org. Investors may also obtain these documents for no charge by visiting the SEC's website at www.sec.gov.
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated clinical activity, including durable complete responses (CRs), and an overall survival (OS) benefit versus historical controls in Phase 1/2 studies of patients with advanced hematological and brain cancer, respectively. For more information about Stemline Therapeutics, visit www.stemline.com.
CONTACT: Stemline Contact: Mark Jacobson Director, Corporate Development Stemline Therapeutics, Inc. 750 Lexington Avenue Sixth Floor New York, NY 10022 Tel: 646-502-2307 Email: email@example.comSource:Stemline Therapeutics, Inc.